clinical trial · NCT05509634
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
Fujian Shengdi Pharmaceutical Co., Ltd.·phase3·completed·n = 754
Prevention of Nausea and Vomiting Caused by Highly Emetogenic ChemotherapyHR20013 for injection；dexamethasonefosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
brief summary
To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.
started
Sep 21, 2022
primary completion
Jun 19, 2023
completion
Aug 30, 2023
last updated
Oct 27, 2023
official title
Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol